An increased prevalence of chronic kidney disease is expected to fuel growth in the nulojix market. The rise in chronic kidney disease is a long-term condition where the kidneys gradually lose their ...

Liaohai “Leo” Chen, a research scientist who oversaw a $20 million surgical robotics training facility while at the ...

The layoffs follow an announcement in early January that I-Mab will re-prioritize resources to focus on advancing a CLDN18.2 ...

Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Many stocks don't offer particularly high yields. The stocks in the S&P 500, for instance, average a yield of just 1.3%. That ...

We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...

A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...

Shares of Bristol Myers Squibb Co. BMY shed 3.04% to $58.76 Tuesday, on what proved to be an all-around positive trading ...

Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.